GoodRx

SGLT2 Inhibitors are used to treat diabetes type 2. They work by removing excess glucose by blocking reabsorption through the kidneys.

 How One Class Of Diabetes Medications May Lead To Flesh-Eating Genital Infections

The U.S. Food and Drug Administration (FDA) issued a warning about a rare but highly disconcerting condition that may occur with the use of a class of type 2 diabetes medications called sodium-glucose cotransporter-2 (SGLT2) inhibitors. The condition is known as necrotizing fasciitis of the perineum or Fournier’s gangrene or "oh $%#&%*."

 SGLT2 Inhibitors: far too many cautions and alerts and limited efficacy

Both the short term and the long term efficacies and safety of SGLT2 inhibitors remain to be established. In fact, these drugs possess much lesser efficacy with far greater costs and undesirable adverse effects with onset of serious adverse outcomes worsening quality of life.

 SGLT2 inhibitors: the story continues to unfold

The sodium–glucose co-transport protein 2 inhibitors (SGLT2is) have had a huge impact on the clinical scene, such as for treatment of diabetes, chronic kidney disease (CKD), and heart failure.

 The bark giving diabetes therapy some bite: the SGLT inhibitors

It was in the 1930s that several critical pieces of information came together to lay the foundations that eventually led to the development of SGLT inhibitors.

SGLT2 Inhibitors: NephMadness

Get under the hood of SGLT2 inhibitors! Listen as our guests Dr. Harish Seethapathy, Dr. Matt Sparks, and Dr. Joel Topf give us a tour through the NephMadness 2020 SGLT2i region! How do these promising drugs work, and what evidence is there for using them in non-diabetic kidney disease or kidney transplant patients;.

SGLT2 Inhibitors and AKI: Time to Ditch the Dogma

In conclusion, robust evidence from clinical studies, propensity-matched analyses, and meta-analyses demonstrate that SGLT2 inhibitor use does not predispose to clinically significant AKI which needs treatment but actually appear to provide protection against AKI.

SGLT2 inhibitors – moving on with the evidence

The evidence base on the benefits and risks of using sodium–glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycaemia has grown in recent years, with data showing potential cardiovascular and renal benefits, along with safety concerns that warrant cautious use and monitoring in certain users.

SGLT2 inhibitors: Sweet (and Salty) Pee

SGLT2i are the wonder drug for our age. But do we know how they work? How does their natriuretic effect actually work? Let’s dig deeper into this week’s mechanistic study that explores this question

An Update on SGLT2 Inhibitors for the Treatment of Diabetes Mellitus

Although there are a wide range of side effects including recently identified episodes of ketoacidosis related to SGLT2 inhibitor use, this class may be a good option in the carefully selected patient. Longer term cardiovascular safety trials are ongoing and will ultimately test the staying power of this class of medications.

Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes

In this comparative effectiveness study analyzing data from the US Department of Veterans Affairs, among patients with type 2 diabetes receiving metformin therapy, SGLT2 inhibitor treatment was associated with a reduced risk of all-cause mortality compared with sulfonylureas. The results provide data from a real-world setting that might help guide the choice of antihyperglycemic therapy.

Development of SGLT1 and SGLT2 inhibitors

Since the cloning of SGLT1 more than 30 years ago, big strides have been made in our understanding of these transporters and their suitability as drug targets. Phlorizin, a naturally occurring competitive inhibitor of SGLT1 and SGLT2, provided the first insights into potential efficacy, but its use was hampered by intestinal side effects and a short half-life. Nevertheless, it was a starting point for the development of specific inhibitors of SGLT1 and SGLT2, as well as dual SGLT1/2 inhibitors.

Harms and benefits of sodium‑glucose co‑transporter 2 inhibitors

SGLT2 inhibitors are oral glucose-lowering drugs which cause modest weight loss and blood pressure reduction. They have low rates of hypoglycaemia, except when used in conjunction with insulin or sulfonylureas. In patients with type 2 diabetes and cardiovascular disease, SGLT2 inhibitors reduce all-cause mortality, rates of hospitalisation for heart failure and the progression of renal disease. Adverse effects are usually mild and related to glycosuria and osmotic diuresis. Serious adverse effects are rare, but may include diabetic ketoacidosis, severe genitourinary infections and possibly lower limb amputations and fractures.

Real-Life Prescribing of SGLT2 Inhibitors: How to Handle the Other Medications, Including Glucose-Lowering Drugs and Diuretics

Despite the overwhelming evidence of the benefits of SGLT2i therapy, the prescription rate remains dismally low, particularly among patients most likely to benefit from cardiorenal protective effects.

SGLT2 inhibitors: a narrative review of efficacy and safety

This narrative review aims to address these issues, to summarize current data relating to the effects of SGLT2 inhibitors on outcomes in patients with T2DM and comorbid conditions, and to provide clinicians with an evidence base that will guide clinical decision-making.

Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits

Besides improving glycaemic control, weight and BP, some members of this class provide beneficial cardiovascular and renoprotective effects. SGLT2 inhibitors should be considered reasonable second-line treatment options for individuals at risk of cardiovascular events or those with underlying nephropathy, if good glycaemic control has not been achieved with metformin monotherapy.

What You Need to Know About SGLT2 Inhibitors

SGLT2i work by inhibiting sodium-glucose cotransporter 2, which is expressed in the proximal renal tubule and is responsible for most glucose reabsorption. Inhibiting sodium-glucose cotransporter 2 reduces reabsorption of filtered glucose and increases glucose excretion through the kidneys. In addition to increasing glucosuria, SGLT2i also reduce sodium reabsorption and appear to act as an osmotic diuretic.

Why Choose Between SGLT2 Inhibitors and GLP1-RA When You Can Use Both?

Although the cardiovascular and kidney benefits of SGLT2i and certain GLP-1RA are well-established, the question remains whether their combined use has any added risk reduction. Despite the lack of definitive evidence, guidelines and society recommendations have promoted the addition of an SGLT2i after a GLP-1RA or vice versa for patients with or at high risk of ASCVD and for patients with chronic kidney disease.